Understanding Drug Sensitivity and Tackling Resistance in Cancer.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
15 04 2022
Historique:
received: 29 10 2021
revised: 21 01 2022
accepted: 15 02 2022
pubmed: 24 2 2022
medline: 19 4 2022
entrez: 23 2 2022
Statut: ppublish

Résumé

Decades of research into the molecular mechanisms of cancer and the development of novel therapeutics have yielded a number of remarkable successes. However, our ability to broadly assign effective, rationally targeted therapies in a personalized manner remains elusive for many patients, and drug resistance persists as a major problem. This is in part due to the well-documented heterogeneity of cancer, including the diversity of tumor cell lineages and cell states, the spectrum of somatic mutations, the complexity of microenvironments, and immune-suppressive features and immune repertoires, which collectively require numerous different therapeutic approaches. Here, we describe a framework to understand the types and biological causes of resistance, providing translational opportunities to tackle drug resistance by rational therapeutic strategies.

Identifiants

pubmed: 35195258
pii: 681719
doi: 10.1158/0008-5472.CAN-21-3695
pmc: PMC9018544
mid: NIHMS1784270
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1448-1460

Subventions

Organisme : NCI NIH HHS
ID : U54 CA224019
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA223976
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA186786
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA224079
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA069533
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA224018
Pays : United States

Informations de copyright

©2022 The Authors; Published by the American Association for Cancer Research.

Références

Nature. 2014 Oct 30;514(7524):628-32
pubmed: 25119024
Clin Cancer Res. 2005 May 15;11(10):3758-65
pubmed: 15897573
Immunotherapy. 2019 Jun;11(8):677-689
pubmed: 31088236
J Clin Oncol. 1999 Jun;17(6):1786-93
pubmed: 10561216
Cancer Cell. 2021 Jul 12;39(7):999-1014.e8
pubmed: 34171263
Proc Natl Acad Sci U S A. 2020 Jun 2;117(22):12315-12323
pubmed: 32424106
Genetics. 2013 Aug;194(4):793-805
pubmed: 23908372
Mol Syst Biol. 2017 Jan 9;13(1):905
pubmed: 28069687
Cancer Discov. 2015 Dec;5(12):1282-95
pubmed: 26516065
Cancer Discov. 2019 Aug;9(8):1050-1063
pubmed: 31088841
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Curr Opin Pharmacol. 2018 Oct;42:102-110
pubmed: 30193150
Cancer Discov. 2019 Jul;9(7):910-925
pubmed: 31048320
Cancer Res. 2008 Jun 15;68(12):4853-61
pubmed: 18559533
Nat Commun. 2019 Jan 16;10(1):244
pubmed: 30651561
Science. 2021 Feb 5;371(6529):602-609
pubmed: 33303685
Eur J Med Chem. 2017 Dec 15;142:271-289
pubmed: 28851502
Drug Resist Updat. 2015 Nov;23:69-78
pubmed: 26341193
Clin Transl Med. 2013 Jan 17;2(1):3
pubmed: 23369605
Cancer Discov. 2017 Jun;7(6):575-585
pubmed: 28274957
Cancer Cell. 2015 Jan 12;27(1):15-26
pubmed: 25584892
Clin Cancer Res. 2005 Oct 15;11(20):7369-75
pubmed: 16243809
Nat Cancer. 2020 Aug;1(8):826-839
pubmed: 33123685
Br J Haematol. 2018 Apr;181(1):11-26
pubmed: 29265356
Elife. 2019 Feb 05;8:
pubmed: 30720426
Nature. 2021 Mar;591(7848):137-141
pubmed: 33361815
Cancer Cell. 2013 Jun 10;23(6):811-25
pubmed: 23764003
Nat Rev Immunol. 2020 Jan;20(1):25-39
pubmed: 31570880
Cancer Res. 2009 Jan 1;69(1):16-22
pubmed: 19117982
Nature. 2012 Jul 26;487(7408):500-4
pubmed: 22763439
Mol Oncol. 2014 Sep 12;8(6):1067-83
pubmed: 24910388
Histopathology. 2010 Aug;57(2):202-11
pubmed: 20716162
J Hematol Oncol. 2020 Sep 24;13(1):127
pubmed: 32972438
Am J Cancer Res. 2020 Dec 01;10(12):4399-4415
pubmed: 33415007
Cell. 2010 Apr 2;141(1):69-80
pubmed: 20371346
Mol Cell Ther. 2014 May 27;2:15
pubmed: 26056583
Nat Med. 2020 Jul;26(7):1054-1062
pubmed: 32461698
J Clin Oncol. 2018 Aug 20;36(24):2492-2503
pubmed: 29985747
Nat Rev Cancer. 2017 Aug;17(8):457-474
pubmed: 28706266
Neoplasia. 2020 Jun;22(6):253-262
pubmed: 32403054
Sci Immunol. 2017 Jul 28;2(13):
pubmed: 28754746
Mol Cell. 2018 Jul 19;71(2):201-215.e7
pubmed: 30029001
Nat Rev Cancer. 2016 Apr;16(4):201-18
pubmed: 27009393
Science. 2017 Jan 6;355(6320):78-83
pubmed: 28059767
Cancer Discov. 2016 Feb;6(2):147-153
pubmed: 26644315
Clin Cancer Res. 2019 Dec 1;25(23):6916-6924
pubmed: 31363002
Haematologica. 2020 Jun;105(6):1527-1538
pubmed: 31439679
J Clin Oncol. 2005 Sep 1;23(25):5900-9
pubmed: 16043828
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
J Bone Miner Res. 2003 Feb;18(2):190-4
pubmed: 12568395
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Cancer Discov. 2018 Dec;8(12):1540-1547
pubmed: 30355724
Cancer Res. 2016 Nov 15;76(22):6471-6482
pubmed: 27671675
Blood Cancer J. 2017 Jun 30;7(6):e581
pubmed: 28665416
Adv Drug Deliv Rev. 2020;165-166:1-14
pubmed: 31790711
Nat Med. 2015 Jun;21(6):560-2
pubmed: 25939061
Mol Oncol. 2014 Sep 12;8(6):1095-111
pubmed: 25087573
Cell. 2020 Nov 12;183(4):860-874
pubmed: 33186528
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Nat Rev Cancer. 2015 Dec;15(12):701-11
pubmed: 26563462
Br J Cancer. 2020 Apr;122(9):1277-1287
pubmed: 32047295
ACS Appl Mater Interfaces. 2019 Nov 13;11(45):41889-41897
pubmed: 31615203
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Nat Commun. 2016 Jul 27;7:12320
pubmed: 27460500
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Front Oncol. 2020 May 12;10:700
pubmed: 32477943
Cell Rep. 2017 Mar 28;18(13):3204-3218
pubmed: 28355571
Cancer Res. 2009 Mar 15;69(6):2305-13
pubmed: 19244107
Nat Commun. 2016 Feb 19;7:10690
pubmed: 26891683
J Clin Oncol. 2006 Oct 10;24(29):4764-74
pubmed: 16954519
Nat Cancer. 2020 Sep;1(9):873-881
pubmed: 35121950
Cancer Cell. 2020 Apr 13;37(4):530-542
pubmed: 32289275
J Clin Invest. 2022 Jul 1;132(13):
pubmed: 35579943
Drug Resist Updat. 2012 Feb-Apr;15(1-2):123-31
pubmed: 22365330
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Leuk Res. 2019 Feb;77:42-50
pubmed: 30642575
Cell. 2012 Mar 16;148(6):1089-98
pubmed: 22424221
J Invest Dermatol. 2022 May;142(5):1401-1412.e20
pubmed: 34699906
Nat Commun. 2019 Nov 14;10(1):5167
pubmed: 31727888
Nat Commun. 2021 Aug 18;12(1):5024
pubmed: 34408137
Nature. 2017 Nov 9;551(7679):247-250
pubmed: 29088702
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
N Engl J Med. 2014 Jun 12;370(24):2352-4
pubmed: 24869597
Cell. 2020 Jul 23;182(2):497-514.e22
pubmed: 32579974
Br J Cancer. 2004 Aug 31;91(5):966-71
pubmed: 15280921
Cell. 2020 Sep 3;182(5):1232-1251.e22
pubmed: 32822576
Mol Cell. 2014 Jun 5;54(5):716-27
pubmed: 24905005
Nature. 2012 Apr 15;485(7397):260-3
pubmed: 22504184
Nat Commun. 2020 Dec 7;11(1):6299
pubmed: 33288764
Cancer Discov. 2018 Oct;8(10):1237-1249
pubmed: 30045908
Cancer Res. 2013 May 1;73(9):2709-17
pubmed: 23610447
Nat Rev Cancer. 2020 Dec;20(12):743-756
pubmed: 33033407
Clin Cancer Res. 2016 Apr 1;22(7):1572-82
pubmed: 26660519
Clin Cancer Res. 2015 Sep 15;21(18):4133-42
pubmed: 25995342
Blood. 2014 Mar 6;123(10):1516-24
pubmed: 24408322
Oncogene. 2006 Mar 13;25(11):1679-91
pubmed: 16550168
Biomed Pharmacother. 2020 Aug;128:110255
pubmed: 32446113
Pharmacogenomics. 2008 Jan;9(1):105-27
pubmed: 18154452
Nat Med. 2014 May;20(5):548-54
pubmed: 24705333
Science. 2017 Jan 6;355(6320):84-88
pubmed: 28059768
Clin Cancer Res. 2010 Dec 1;16(23):5664-78
pubmed: 20829328
Immunity. 2017 Oct 17;47(4):789-802.e9
pubmed: 29045907
Nat Rev Cancer. 2020 Jan;20(1):26-41
pubmed: 31601988
N Engl J Med. 2005 Feb 24;352(8):786-92
pubmed: 15728811
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
JAMA Oncol. 2019 Jan 1;5(1):96-103
pubmed: 30098166
Blood. 2019 Feb 7;133(6):588-599
pubmed: 30425048
Nature. 2018 Oct;562(7728):526-531
pubmed: 30333627
Clin Cancer Res. 2014 Apr 1;20(7):1757-1767
pubmed: 24398047
Cancer Cell. 2021 Aug 9;39(8):1150-1162.e9
pubmed: 34115987
Cancer Discov. 2014 Jan;4(1):94-109
pubmed: 24265153
Blood. 2019 Feb 14;133(7):676-687
pubmed: 30510081
Cancer Res. 2018 Oct 1;78(19):5680-5693
pubmed: 30115691
Cancer Discov. 2019 Mar;9(3):342-353
pubmed: 30514704
Nat Rev Clin Oncol. 2018 Jun;15(6):366-381
pubmed: 29651130
Signal Transduct Target Ther. 2020 Mar 12;5(1):28
pubmed: 32296047
Br J Haematol. 2016 Mar;172(6):983-6
pubmed: 26095727
Cancer Cell. 2020 Jan 13;37(1):104-122.e12
pubmed: 31935369
Neurooncol Adv. 2021 Feb 08;3(1):vdab023
pubmed: 33758825
Oncogene. 2010 Aug 26;29(34):4741-51
pubmed: 20531305
Biochem Biophys Res Commun. 2019 Sep 10;517(1):36-42
pubmed: 31311651
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
Cell. 2018 Aug 9;174(4):843-855.e19
pubmed: 30017245
Nat Chem Biol. 2020 Apr;16(4):469-478
pubmed: 32152546
Leukemia. 2019 Feb;33(2):447-456
pubmed: 30026573
J Clin Oncol. 2017 Sep 10;35(26):3065-3074
pubmed: 28498782
Haematologica. 2020 Mar;105(3):708-720
pubmed: 31296572
Genes (Basel). 2020 Dec 16;11(12):
pubmed: 33339226
AAPS J. 2015 Jan;17(1):65-82
pubmed: 25236865
Oncotarget. 2017 Jan 17;8(3):3933-3945
pubmed: 27965469
Front Immunol. 2020 Oct 21;11:2166
pubmed: 33193295
Nat Med. 2016 Mar;22(3):262-9
pubmed: 26828195
Science. 2019 Dec 20;366(6472):1473-1480
pubmed: 31699882
Nat Rev Cancer. 2012 Apr 05;12(5):349-61
pubmed: 22475929
Clin Cancer Res. 2020 Apr 1;26(7):1633-1643
pubmed: 31776128
Cancer Discov. 2016 Oct;6(10):1118-1133
pubmed: 27432227
Cancer Cell. 2021 Jun 14;39(6):779-792.e11
pubmed: 34087162
Front Pharmacol. 2015 Sep 01;6:181
pubmed: 26388771
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33495298
Nat Genet. 2015 Mar;47(3):250-6
pubmed: 25665005
Cancer Cell. 2010 Jan 19;17(1):77-88
pubmed: 20129249
Am Soc Clin Oncol Educ Book. 2019 Jan;39:147-164
pubmed: 31099674
Clin Cancer Res. 2014 Mar 15;20(6):1590-600
pubmed: 24449822
Nature. 2021 Aug;596(7873):576-582
pubmed: 34381210
Pharmacol Rev. 2006 Sep;58(3):621-81
pubmed: 16968952
Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12425-30
pubmed: 21746895
NPJ Breast Cancer. 2021 Jan 21;7(1):5
pubmed: 33479246
Proc Natl Acad Sci U S A. 2021 Aug 10;118(32):
pubmed: 34353917
Leukemia. 2020 Jun;34(6):1684-1688
pubmed: 31844143
Leukemia. 2019 Apr;33(4):863-883
pubmed: 30683909
Nature. 2019 Aug;572(7769):402-406
pubmed: 31341276
Sci Transl Med. 2015 Apr 15;7(283):283ra51
pubmed: 25877889
Cancer Cell. 2020 Apr 13;37(4):584-598.e11
pubmed: 32220301
Nat Commun. 2020 Apr 29;11(1):2089
pubmed: 32350277
Cell Stem Cell. 2017 Feb 2;20(2):233-246.e7
pubmed: 27989769
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
Cell Death Dis. 2013 Oct 10;4:e838
pubmed: 24113172
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Clin Cancer Res. 2021 Feb 1;27(3):759-774
pubmed: 33199493
Oncoimmunology. 2018 Jul 23;7(10):e1486948
pubmed: 30288349
Nat Rev Cancer. 2012 Jun 14;12(7):487-93
pubmed: 22695393
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Blood. 2017 Mar 16;129(11):e26-e37
pubmed: 28122742
Nature. 2014 Apr 3;508(7494):118-22
pubmed: 24670642
Nature. 2015 Jan 8;517(7533):209-13
pubmed: 25470039
Mol Cancer Ther. 2013 Jun;12(6):1140-50
pubmed: 23536725
Cell. 2013 Dec 5;155(6):1309-22
pubmed: 24315100
PLoS Med. 2005 Mar;2(3):e73
pubmed: 15737014
Nat Genet. 2017 Dec;49(12):1693-1704
pubmed: 29106415
Immunity. 2016 Jun 21;44(6):1255-69
pubmed: 27332730
Nat Med. 2016 May 5;22(5):472-8
pubmed: 27149220
PLoS One. 2011;6(7):e22769
pubmed: 21829508
Molecules. 2014 Sep 04;19(9):13848-77
pubmed: 25191874
Nature. 2018 Jul;559(7712):125-129
pubmed: 29950729
Blood. 2008 Sep 15;112(6):2489-99
pubmed: 18565852
Cancer Discov. 2021 Apr;11(4):900-915
pubmed: 33811123
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
Cancer Discov. 2020 Apr;10(4):536-551
pubmed: 31974170
Science. 2014 Oct 10;346(6206):251-6
pubmed: 25301630
Blood Cancer Discov. 2021 Sep;2(5):518-531
pubmed: 34568834
Nature. 2017 Jun 15;546(7658):431-435
pubmed: 28607484
Cancer Lett. 2019 Jan;440-441:82-93
pubmed: 30315846
Nat Rev Cancer. 2018 Jul;18(7):452-464
pubmed: 29643473
Nat Biotechnol. 2021 Oct;39(10):1246-1258
pubmed: 34083792
Cell Rep. 2015 Apr 7;11(1):98-110
pubmed: 25843712
N Engl J Med. 2014 Jun 12;370(24):2286-94
pubmed: 24869598
Nat Metab. 2020 Apr;2(4):318-334
pubmed: 32691018
Blood. 2016 May 19;127(20):2406-10
pubmed: 26907630
Nature. 2012 Jan 18;481(7381):306-13
pubmed: 22258609
Nat Rev Cancer. 2017 Dec;17(12):738-750
pubmed: 29123246

Auteurs

Jeffrey W Tyner (JW)

Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.

Franziska Haderk (F)

Department of Medicine, University of California, San Francisco, San Francisco, California.
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California.

Anbarasu Kumaraswamy (A)

Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.

Linda B Baughn (LB)

Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

Brian Van Ness (B)

Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, Minnesota.

Song Liu (S)

Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Himangi Marathe (H)

Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Joshi J Alumkal (JJ)

Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.

Trever G Bivona (TG)

Department of Medicine, University of California, San Francisco, San Francisco, California.
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California.

Keith Syson Chan (KS)

Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California.
Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California.

Brian J Druker (BJ)

Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.

Alan D Hutson (AD)

Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Peter S Nelson (PS)

Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington.
Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Charles L Sawyers (CL)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, New York.
Howard Hughes Medical Institute, Chevy Chase, Maryland.

Christopher D Willey (CD)

Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH